HANS MOEBIUS - 22 Jun 2022 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role
Chief Medical Officer
Signature
/s/ Glenna Mileson, Attorney-in-Fact for Hans Moebius
Issuer symbol
ATHA
Transactions as of
22 Jun 2022
Net transactions value
+$11,995
Form type
4
Filing time
24 Jun 2022, 19:54:04 UTC
Previous filing
20 Jan 2022
Next filing
30 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATHA Common Stock Award $11,995 +1,699 +5.4% $7.06 32,955 18 May 2022 Direct F1, F2, F3
transaction ATHA Common Stock Award $0 +10,000 +30% $0.000000 42,955 22 Jun 2022 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of November 18, 2021 through May 18, 2022. This transaction is also exempt under Rule 16b-3(c).
F2 The Purchase Period ended May 18, 2022 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began November 18, 2021.
F3 In accordance with the ESPP, these shares were purchased based on 85% of the closing price on May 18, 2022.
F4 On November 3, 2021, the reporting person was granted restricted stock units ("RSUs") representing 30,000 shares of Common Stock of the Issuer. The RSUs were scheduled to vest according to the following schedule: (1) one third (1/3rd) of the number of shares subject to the RSU award vest at the completion of the public readout of topline results of the Issuer's ACT-AD Phase 2 clinical trial; (2) one third (1/3rd) of the number of shares subject to the RSU award vest at the completion of the public readout of topline results of the Issuer's LIFT-AD Phase 2/3 clinical trial (the "LIFT-AD Readout") and (3) one third (1/3rd) of the number of shares subject to the RSU award vest six (6) months after the LIFT-AD Readout, in each case subject to continued service with the Issuer through the applicable vesting date. On June 22, 2022, the Issuer completed the public readout of topline results of the ACT-AD Phase 2 clinical trial and 10,000 RSUs vested and settled on such date.